PMID- 33714407 OWN - NLM STAT- MEDLINE DCOM- 20210727 LR - 20210727 IS - 2213-3763 (Electronic) IS - 0019-4832 (Print) IS - 0019-4832 (Linking) VI - 73 IP - 1 DP - 2021 Jan-Feb TI - Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. PG - 35-43 LID - S0019-4832(20)30458-2 [pii] LID - 10.1016/j.ihj.2020.12.008 [doi] AB - OBJECTIVES: The no-reflow phenomenon occurs in 25% of patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), and may be associated with adverse outcomes. The aim of our study was to detect novel predictors of no-reflow phenomenon and the resulting adverse long term outcomes. METHODS: We enrolled 400 STEMI patients undergoing primary PCI; 228 patients had TIMI flow 3 after PCI (57%) and the remaining 172 patients had TIMI flow <3 (43%). Fibrinogen to albumin ratio (FAR), high sensitive C-reactive protein to albumin ratio (CAR), and atherogenic index of plasma (AIP) were calculated. Long term mortality and morbidity during 6 months follow up were recorded. These data were compared among both groups. RESULTS: In multivariate regression analysis, old age (OR = 1.115, 95% CI: 1.032-1.205, P = 0.006), higher troponin level >5.6 ng/mL (OR = 1.040, 95% CI: 1.001-1.080, P = 0.04), diabetes mellitus (OR = 4.401, 95% CI: 1.081-17.923, P = 0.04) and heavy thrombus burden (OR = 16.915, 95% CI: 5.055-56.602, P < 0.001) could be considered as predictors for the development of no-reflow. Interestingly, CAR >0.21, FAR >11.56, and AIP >0.52 could be considered as novel powerful independent predictors (OR = 3.357, 95% CI: 2.288-4.927, P < 0.001, OR = 4.187, 95% CI: 2.761-6.349, P < 0.001, OR = 16.794, 95% CI: 1.018-277.01, P = 0.04, respectively). Higher long term mortality (P < 0.001) and heart failure (P < 0.001) was also strongly related to incidence of no-reflow. CONCLUSION: No-reflow could be attributed to novel predictors as CAR, FAR, and AIP. This phenomenon was associated with long term adverse events as higher mortality and pump failure. CI - Copyright (c) 2020 Cardiological Society of India. Published by Elsevier B.V. All rights reserved. FAU - Refaat, Hesham AU - Refaat H AD - Cardiology Department, Zagazig University, Zagazig, Egypt. Electronic address: heshamrefat22@yahoo.com. FAU - Tantawy, Ayman AU - Tantawy A AD - Cardiology Department, Zagazig University, Zagazig, Egypt. FAU - Gamal, Amr S AU - Gamal AS AD - Cardiology Department, Zagazig University, Zagazig, Egypt. FAU - Radwan, Hanan AU - Radwan H AD - Cardiology Department, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article PT - Observational Study DEP - 20201229 PL - India TA - Indian Heart J JT - Indian heart journal JID - 0374675 SB - IM MH - Aged MH - Coronary Angiography MH - Coronary Circulation/*physiology MH - Cross-Sectional Studies MH - Egypt/epidemiology MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - No-Reflow Phenomenon/diagnosis/epidemiology/*etiology MH - Percutaneous Coronary Intervention/*methods MH - Retrospective Studies MH - Risk Assessment/*methods MH - Risk Factors MH - ST Elevation Myocardial Infarction/diagnosis/*physiopathology/surgery MH - Time Factors PMC - PMC7961261 OTO - NOTNLM OT - Myocardial infarction OT - No-reflow OT - Novel predictors OT - Outcomes COIS- Declaration of competing interest There is no conflict of interests. EDAT- 2021/03/15 06:00 MHDA- 2021/07/28 06:00 PMCR- 2021/01/01 CRDT- 2021/03/14 20:20 PHST- 2020/09/08 00:00 [received] PHST- 2020/10/27 00:00 [revised] PHST- 2020/12/17 00:00 [accepted] PHST- 2021/03/14 20:20 [entrez] PHST- 2021/03/15 06:00 [pubmed] PHST- 2021/07/28 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - S0019-4832(20)30458-2 [pii] AID - 10.1016/j.ihj.2020.12.008 [doi] PST - ppublish SO - Indian Heart J. 2021 Jan-Feb;73(1):35-43. doi: 10.1016/j.ihj.2020.12.008. Epub 2020 Dec 29.